Impact of a step therapy for guanfacine extended-release on medication utilization and health care expenditures among individuals receiving treatment for ADHD

Journal of Managed Care Pharmacy

Volumn 21, Issue 9, 2015, Pages 793-802

  Suehs, Brandon T ^a   Sikirica, Vanja ^b   Mudumby, Pallavi ^a   Dufour, Robert ^a   Patel, Nick C ^a  

^a Formerly of Comprehensive Health Insights Inc   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMPHETAMINE; ATOMOXETINE; CLONIDINE; GUANFACINE; METHYLPHENIDATE; PRESCRIPTION DRUG; PSYCHOSTIMULANT AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; DELAYED RELEASE FORMULATION;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; COHORT ANALYSIS; CONTROLLED DRUG RELEASE; DRUG COST; DRUG UTILIZATION; FEMALE; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE POLICY; HUMAN; MALE; RETROSPECTIVE STUDY; THERAPY DELAY; TREATMENT OUTCOME; ADJUVANT THERAPY; ADMINISTRATIVE CLAIMS (HEALTH CARE); CHILD PSYCHIATRY; CONTROLLED STUDY; DEMOGRAPHY; DRUG APPROVAL; DRUG FORMULARY; DRUG THERAPY; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEALTH CARE UTILIZATION; MAJOR CLINICAL STUDY; MENTAL HEALTH CARE; MENTAL HEALTH CARE PERSONNEL; MENTAL PATIENT; MONOTHERAPY; PHARMACY; PRESCRIPTION; STEP THERAPY; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DELAYED RELEASE FORMULATION; ECONOMICS; HEALTH INSURANCE; INSURANCE; TIME FACTOR; UNITED STATES;

ADOLESCENT; ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; COHORT STUDIES; DELAYED-ACTION PREPARATIONS; FEMALE; GUANFACINE; HEALTH CARE COSTS; HEALTH EXPENDITURES; HUMANS; INSURANCE COVERAGE; MALE; MANAGED CARE PROGRAMS; RETROSPECTIVE STUDIES; TIME FACTORS; UNITED STATES;

EID: 84946414829     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2015.21.9.793     Document Type: Article

References (29)

1. Shoemaker SJ, Pozniak A, Subramanian R, Mauch D. Effect of 6 managed care pharmacy tools: a review of the literature. J Manag Care Pharm. 2010;16(6a Suppl):S3-S20. Available at: http://www.amcp.org/data/jmcp/JulSuppA.pdf.
2. Motheral BR. Pharmaceutical step-therapy interventions: a critical review of the literature. J Manag Care Pharm. 2011;17(2):143-55. Available at: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=8983.
3. Pharmacy Benefit Management Institute. 2011-2012 Prescription drug benefit cost and plan design online report. Utilization management. Available at: http://reports.pbmi.com/report.php?id=6. Accessed August 5, 2015.
4. Farley JF, Cline RR, Schommer JC, Hadsall RS, Nyman JA. Retrospective assessment of Medicaid step-therapy prior authorization policy for atypical antipsychotic medications. Clin Ther. 2008;30(8):1524-39; discussion 1506-07.
5. Mark TL, Gibson TM, McGuigan K, Chu BC. The effects of antidepressant step therapy protocols on pharmaceutical and medical utilization and expenditures. Am J Psychiatry. 2010;167(10):1202-09. Available at: http://ajp. psychiatryonline.org/article.aspx?articleid=102459. Accessed August 5, 2015.
6. Soumerai SB, Zhang F, Ross-Degnan D, et al. Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change. Health Aff (Millwood). 2008;27(3):w185-95. Available at: https://www.legis.iowa.gov/docs/publications/IH/9375.pdf. Accessed August 5, 2015.
7. Zhang Y, Adams AS, Ross-Degnan D, Zhang F, Soumerai SB. Effects of prior authorization on medication discontinuation among Medicaid beneficiaries with bipolar disorder. Psychiatr Serv. 2009;60(4):520-27. Available at: http://ps.psychiatryonline.org/doi/pdf/10.1176/ps.2009.60.4.520. Accessed August 17, 2015.
8. Muir VJ, Perry CM. Guanfacine extended-release: in attention deficit hyperactivity disorder. Drugs. 2010;70(13):1693-702.
9. Sikirica V, Xie J, He T, et al. Immediate-release versus extended-release guanfacine for treatment of attention-deficit/hyperactivity disorder. Am J Pharm Benefits. 2013;5(4):e85-e94. Available at: http://www.ajmc.com/publications/ajpb/2013/AJPB_JulAug2013/Immediate-Release-Versus-Extended-Release-Guanfacine-for-Treatment-of-Attention-DeficitHyperactivity-Disorder. Accessed August 5, 2015.
10. Chappell PB, Riddle MA, Scahill L, et al. Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry. 1995;34(9):1140-46.
11. Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry. 2001;158(7):1067-74. Available at: http://ajp.psychiatryonline.org/article.aspx?articleid=174881. Accessed August 5, 2015.
12. Taylor FB, Russo J. Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2001;21(2):223-28.
13. Hunt RD, Minderaa RB, Cohen DJ. Clonidine benefits children with attention deficit disorder and hyperactivity: report of a double-blind placebo-crossover therapeutic trial. J Am Acad Child Psychiatry. 1985;24(5):617-29.
14. Connor DF, Fletcher KE, Swanson JM. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1999;38(12):1551-59.
15. Betts KA, Sikirica V, Hodgkins P, et al. Period prevalence of concomitant psychotropic medication usage among children and adolescents with attention-deficit/hyperactivity disorder during 2009. J Child Adolesc Psychopharmacol. 2014;24(5):260-68.
16. Sikirica V, Pliszka SR, Betts KA, et al. Impact of atypical antipsychotic use among adolescents with attention deficit/hyperactivity disorder. Am J Manag Care. 2014;20(9):711-21. Available at: http://www.ajmc.com/publications/issue/2014/2014-vol20-n9/impact-of-atypical-antipsychotic-useamong-adolescents-with-attention-deficithyperactivity-disorder/3. Accessed August 5, 2015.
17. Sikirica V, Pliszka SR, Betts KA, et al. Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics. J Manag Care Pharm. 2012;18(9):676-89. Available at: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=15872.
18. Happe LE, Clark D, Holliday E, Young T. A systematic literature review assessing the directional impact of managed care formulary restrictions on medication adherence, clinical outcomes, economic outcomes, and health care resource utilization. J Manag Care Spec Pharm. 2014;20(7):677-84. Available at: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=18257.
19. Yokoyama K, Yang W, Preblick R, Frech-Tamas F. Effects of a step-therapy program for angiotensin receptor blockers on antihypertensive medication utilization patterns and cost of drug therapy. J Manag Care Pharm. 2007;13(3):235-44. Available at: http://www.amcp.org/data/jmcp/235-44.pdf.
20. Delate T, Mager DE, Sheth J, Motheral BR. Clinical and financial outcomes associated with a proton pump inhibitor prior-authorization program in a Medicaid population. Am J Manag Care. 2005;11(1):29-36. Available at: http://www.ajmc.com/publications/issue/2005/2005-01-vol11-n1/Jan05-1977p029-036/. Accessed August 5, 2015.
21. Shaw M, Hodgkins P, Caci H, et al. A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment. BMC Med. 2012;10:99. Available at: http://www.biomedcentral.com/1741-7015/10/99. Accessed August 5, 2015.
22. Arnold LE, Hodgkins P, Kahle J, Madhoo M, Kewley G. Long-term outcomes of ADHD: academic achievement and performance. J Atten Disord. 2015 Jan 12. [Epub ahead of print]
23. Harpin V, Mazzone L, Raynaud JP, Kahle J, Hodgkins P. Long-term outcomes of ADHD: a systematic review of self-esteem and social function. J Atten Disord. 2013 May 22. [Epub ahead of print]
24. Parker J, Wales G, Chalhoub N, Harpin V. The long-term outcomes of interventions for the management of attention-deficit hyperactivity disorder in children and adolescents: a systematic review of randomized controlled trials. Psychol Res Behav Manag. 2013;6:87-99.
25. Shaw M, Hodgkins P, Caci H, et al. A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment. BMC Med. 2012;10:99.
26. Hong J, Novick D, Treuer T, et al. Predictors and consequences of adherence to the treatment of pediatric patients with attention-deficit/hyperactivity disorder in Central Europe and East Asia. Patient Prefer Adherence. 2013;7:987-95.
27. Cox ER, Henderson R, Motheral BR. Health plan member experience with point-of-service prescription step therapy. J Manag Care Pharm. 2004;10(4):291-98. Available at: http://www.amcp.org/data/jmcp/Research-291-298.pdf.
28. Virabhak S, Shinogle JA. Physicians' prescribing responses to a restricted formulary: the impact of Medicaid preferred drug lists in Illinois and Louisiana. Am J Manag Care. 2005;11(Spec No):SP14-SP20.
29. Motheral BR, Henderson R, Cox ER. Plan-sponsor savings and member experience with point-of-service prescription step therapy. Am J Manag Care. 2004;10(7 Pt 1):457-64.